We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Adam H. Golden

New York

Adam H. Golden

Head of the Corporate Practice Group in New York, Adam Golden advises life sciences companies on their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer, with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.

Over his career, Adam has advised clients on M&A, capital markets transactions, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.

Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000.

"Adam Golden is an M&A and licensing expert who regularly represents clients in both acquisitions and divestments of multi-billion dollar business units."

LMG Life Sciences

Representative Experience

Advised Novartis in the acquisition of GSK's oncology business for up to US$16bn.

Advised Allergan in the acquisition of rights to Ironwood Pharmaceuticals' linaclotide product (CONSTELLA®) in more than 40 countries outside the U.S.

Counseled Sandoz in the acquisition of Fougera Pharmaceuticals for approximately US$1.5bn.

Helped Celgene in R&D collaborations and options to acquire research-stage biotech companies.

Assisted Pfizer in the acquisition of NextWave Pharmaceuticals for up to US$700m.

Counseled principal stockholder of iMDsoft in its sale to TPG Capital.

Guided Vatera Healthcare in venture capital investments in biopharmaceutical companies.

Aided Novartis in exclusive global collaboration agreement with the University of Pennsylvania to develop and commercialize immunotherapies for cancer.

Education and admissions


  • J.D., New York University School of Law, 1990
  • A.B., Princeton University, 1986

Bar admissions and qualifications

  • New York
  • Massachusetts


Nationwide, Life Sciences: Corporate/Commercial

Chambers USA


Global-wide, Life Sciences: Corporate/Commercial

Chambers Global


Life Sciences - Transactional

Who's Who Legal


The World's Leading Patent Practitioners

IAM Patent 1000


Life Sciences Star - Finance & Transactional

LMG Life Sciences

2011, 2013-2015

Healthcare: Life Sciences

Legal 500 US


Leading Lawyers for Business

Chambers USA

Latest thinking and events

View More
Loading data